PAPEL DE LOS BIFOSFONATOS PARA EL TRATAMIENTO DE LAS METASTASIS OSEAS Y EL MANTENIMIENTO DE LA SALUD OSEA
Columnista Experta de SIIC Allan Lipton
en colaboración con
Primera edición en siicsalud:
3 de octubre, 2005
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/72901
Especialidad principal:
Oncología
Especialidades relacionadas:
Medicina Farmacéutica,Medicina Interna,
Lipton A. Toward new horizons: the future of bisphosphonate therapy, Oncologist 9(9):38-47, 2004
Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid, Clin Cancer Res 10(10):6397S-403S, 2004
Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference, Clin Cancer Res 10(10):6277S-81S, 2004
Lipton AM, White CL 3rd, Bigio EH. Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration, Acta Neuropathol (Berl) 108(108):379-85, 2004
Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention, J Support Oncol 2(2):205-13, 2004
Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer, Clin Breast Cancer 5(5):105-16, 2004
Lipton AM, Benavides R, Hynan LS, Bonte FJ, Harris TS, White CL 3rd, Bigio EH. Lateralization on neuroimaging does not differentiate frontotemporal lobar degeneration from Alzheimer's disease, Dement Geriatr Cogn Disord 17(17):324-7, 2004
Allan Lipton
